Advanced Search

Oncology & Hematology Coding Alert

Estrogen Receptor Status:

3 Questions Clarify V86.0 Use for Current Breast Cancer Coding Success

Published on Tue May 25, 2010

Learn which code you should add for patients on tamoxifen therapy.Skipping secondary ICD-9 codes can be tempting, but properly reporting estrogen receptor status is a quick way to add support to your breast cancer patients' claims. Shore up your V86.x coding skills with the answers to three key questions.Important: These questions and answers relate to patients being treated for breast cancer that is currently present, not for patients on prophylactic regimens.1. What Do ER+ and ER- Refer To?The following codes describe estrogen receptor status:V86.0 -- Estrogen receptor positive status [ER+]V86.1 -- Estrogen receptor negative status [ER-].When a neoplasm is ER+, estrogen is fueling the cancer and causing it to grow. As a result, ER+ cancer should respond to hormone therapy. ER- cancers won't respond as well to hormone therapy. So ER status is important information for the oncologist when making treatment decisions.Treatments: Hormone therapies that V86.0 may help support include the following: [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All